Catalyst OrthoScience, a private medical technology company focused on advancing shoulder arthroplasty through simplified, surgeon-centric innovation, announced that it has raised $15 million in new equity and debt financing. The funding round was led by RC Capital, with participation from Mutual Capital Partners, Dr. Derace Schaffer, and Western Alliance Bank, Member FDIC.
The new funding strengthens Catalyst’s financial position and will support continued growth across its commercial and clinical programs. The company’s differentiated shoulder replacement systems — including the recently launched Catalyst Fracture Shoulder System — are gaining traction among surgeons who value its streamlined design and focus on improving outcomes while simplifying surgical procedures.
In addition to the new financing, Catalyst announced the appointment of Dr. Theodore Blaine, an orthopedic shoulder surgeon at the Hospital for Special Surgery (HSS), to its board of directors. Dr. Blaine brings deep clinical expertise in shoulder surgery and a strong commitment to evidence-based medical innovation.
Dr. Derace Schaffer, a physician, entrepreneur, and long-time Catalyst investor and board member, also reaffirmed his confidence in the company’s leadership and strategy. With extensive experience founding and guiding healthcare ventures through successful public and private exits, Dr. Schaffer’s continued involvement highlights the long-term strength of Catalyst’s governance and investor base.
Catalyst OrthoScience, founded in 2014 by orthopedic surgeon Dr. Steven Goldberg, is headquartered in Naples, Florida. The company has built a reputation for engineering precision shoulder replacement systems designed to preserve bone and soft tissue, reduce complications, and restore natural movement. Its solutions reflect the company’s broader vision of advancing orthopedic surgery through innovation that prioritizes both patient outcomes and surgical efficiency.
How the funding will be used: Catalyst plans to use the funds to accelerate the adoption of its technology, expand its U.S. footprint, and further strengthen its research and development pipeline. With a growing surgeon base, expanding presence across hospitals and ambulatory surgery centers (ASCs), and increasing investor confidence, Catalyst continues to execute on its mission to simplify complex orthopedic procedures without compromising quality or results.
KEY QUOTES:
“Catalyst epitomizes what can be accomplished by combining continuous innovation with excellence and employee dedication. As an investor and board member across many public and private healthcare companies, I’ve seen how important it is for a team to execute with both clinical integrity and operational precision. Catalyst stands out as a company that’s not only building value but protecting it – with the leadership, resources, and investor conviction to succeed regardless of any challenge it may face.”
Dr. Derace Schaffer, Physician, Entrepreneur, and Catalyst Board Member
“As a surgeon, I’ve been impressed by Catalyst’s commitment to evidence-based design that has earned the enduring support of its investors. The company’s innovations improve patient outcomes while also simplifying surgical workflow. With its disciplined execution, Catalyst is providing a compelling combination of clinical value and efficiency.”
Dr. Theodore Blaine, Orthopedic Shoulder Surgeon, Hospital for Special Surgery (HSS), and Catalyst Board Member
